Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 3Terminated 2Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 13Dermatologic 11Head & Neck 6Tumor-Agnostic 3Genitourinary 3Gastrointestinal 3Sarcoma 2Breast 2Plasma cell 1Gynecologic 1CNS 1

Conditions

Glioblastoma 1

Interventions

Temozolomide 59Radiotherapy 37Magnetic Resonance Spectroscopy 32Radiosurgery 27Specimen Handling 23Cyclophosphamide 21pembrolizumab 20Nivolumab 20Radiation 17Carboplatin 12Biopsy 12Bevacizumab 11Vincristine 10Ipilimumab 10Cisplatin 10X-Rays 9Lomustine 8Irinotecan 8Immunoglobulin G 8Etoposide 8trametinib 7Disulfides 7AZD 6244 7pertuzumab 6atezolizumab 6abemaciclib 6Topotecan 6Proton Therapy 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × cemiplimab × CNS × Clear all
NCT03491683 2026-05-04

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Inovio Pharmaceuticals

Phase 1/2 Active not recruiting
52 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡